The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when
administered in combination with tirzepatitide in overweight or obese participants. The study
will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the
body to remove it in overweight or obese participants. The study will last up to
approximately 11 weeks.